Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine’s first-in-class monoclonal antibody drug, HMI-115. The first-in-class mAb will benefit endometriosis and androgenetic alopecia […]

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. September 19, Wuhan, China […]

Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally Leads Biolabs and Chime Biologics initiate strategic cooperation to accelerate IND application and provide clinical trial materials in China. BeiGene and Chime Biologics establish strategic cooperation to facilitate IND applications overseas and clinical trial materials Chime Biologics, […]